Skip to main content
The Egyptian Heart Journal

Table 2 baseline characteristics of the participants

From: Soluble guanylate cyclase stimulators for heart failure: a network meta-analysis and subgroup analyses of reduced and preserved ejection fraction

Study ID

Arm

Number of patients

Age (years), mean (SD)

Gender (male), N. (%)

BMI, mean (SD)

LVEF (%), mean (SD)

NT-proBNP, mean (SD)

eGFR, mean (SD)

Comorbidities, N. (%)

DM

AF

HTN

CKD

COPD

CAD

Armstrong et al. 2020 (VITALITY-HFpEF) [8]

Vericiguat 10 mg

263

72.2 (9.7)

139 (52.9)

30.4 (6.0)

55.8 (8.3)

1700 (1732)

62.4 (20.6)

115 (43.7)

163 (62.0)

243 (92.4)

92 (35.0)

46 (17.5)

115 (43.7)

Vericiguat 15 mg

264

73.1 (9.1)

124 (47.0)

30.9 (6.2)

56.8 (7.9)

2826.5(1639)

59.1 (21.2)

120 (45.5)

164 (62.1)

243 (92.0)

110 (41.7)

57 (21.6)

120 (45.5)

Placebo

262

72.8 (9.4)

141 (53.8)

30.7 (6.0)

56.3 (7.9)

1867 (1763.2)

56.9 (20.0)

123 (46.9)

158 (60.3)

243 (92.7)

116 (44.3)

51 (19.5)

127 (48.5)

Armstrong et al. 2020 (VICTORIA) [2]

Vericiguat 10 mg

2526

67.5 (12.2)

1921 (76)

27.7 (5.8)

29 (8.3)

3139.75 (1116.3)

61.3 (27)

1226 (48.6)

1098 (43.5)

2002 (79.3)

N/A

431 (17.1)

1511 (59.8)

Placebo

2524

67.2 (12.2)

1921 (76.1)

27.9 (6.1)

28.8 (8.3)

3099 (1068.1)

61.7 (27.3)

1143 (45.3)

1170 (46.4)

1993 (79)

N/A

436 (17.3)

1433 (56.8)

Bonderman et al. 2013 (LEPHT) [10]

Riociguat 0.5 mg

26

57.2 (36–78)

26 (81)

29.2 (5.7)

27 (5)

1923 (1411.8)

72 (18.1)

13 (41)

3 (10)

N/A

N/A

N/A

N/A

Riociguat 1 mg

30

55.1 (28–74)

30 (91)

28.2 (4.6)

28.8 (4.6)

2417 (2730.4)

72.6 (23)

10 (30)

3 (9)

N/A

N/A

N/A

N/A

Riociguat 2 mg

55

59.3 (26–76)

55 (82)

28.9 (4.9)

28.4 (5.7)

2175 (2335.2)

65.1 (18.8)

30 (45)

9 (16)

N/A

N/A

N/A

N/A

Placebo

61

58.9 (25–79)

61 (88)

28.7 (5.8)

27.1 (5)

3000 (3472.2)

68.7 (19.9)

34 (49)

9 (15)

N/A

N/A

N/A

N/A

Bonderman et al. 2014 (DILATE-1) [7]

Riociguat 0.5 mg

8

68.3 (48.0–80.0)

1 (13)

33.5 (22.9–44.9)

N/A

1765 (1323)

N/A

4 (50)

4 (50)

N/A

N/A

1 (13)

2 (25)

Riociguat 1 mg

7

65.3 (52.0–79.0)

3 (43)

31.0 (21.6–40.8)

N/A

852 (444)

N/A

3 (43)

3 (43)

N/A

N/A

0 (0)

1 (14)

Riociguat 2 mg

10

72.8 (59.0–83.0)

5 (50)

29.3 (23.5–33.4)

N/A

2537 (2394)

N/A

4 (40)

3 (30)

N/A

N/A

2 (20)

2 (20)

Placebo

11

75.1 (65.0–86.0)

6 (45)

30.2 (21.8–36.0)

N/A

2195 (1316)

N/A

5 (11)

6 (55)

N/A

N/A

4 (36)

1 (9)

Dachs et al. 2022 (haemoDYNAMIC) [9]

Riociguat up-titrated 1.5 mg

58

70.6 (8.0)

12 (20.7)

32.1 (6.4)

61.0 (6.7)

819.6

63.4 (21.9)

16 (27.6)

36 (62.1)

38 (65.5)

27 (46.6)

5 (8.6)

7 (12.1)

Placebo

56

72.1 (8.5)

19 (33.9)

30.3 (6.4)

60.1 (6.0)

1051.3

61.7 (20.1)

16 (28.6)

37 (66.1)

34 (60.7)

27 (48.2)

5 (8.9)

8 (14.3)

Gheorghiade et al. 2015 (SOCRATES-Reduced) [6]

Vericiguat 1.25 mg

91

68 (13)

70 (76.9)

28 (6)

29.5 (8.6)

3529 (3562)

57.2 (21.0)

36 (39.6)

32 (35.2)

71 (78.0)

35 (38.5)

N/A

46 (50.5)

Vericiguat 2.5 mg

91

68 (12)

72 (79.1)

28 (5)

29.2 (8.2)

2921 (2452)

56.9 (19.1)

54 (59.3)

30 (33.0)

70 (76.9)

41 (45.1)

57 (62.6)

Vericiguat 5 mg

91

67 (12)

74 (81.3)

29 (5)

31.5 (8.5)

4229 (5248)

60.1 (20.2)

39 (42.9)

30 (33.0)

68 (74.7)

37 (40.7)

42 (46.2)

Vericiguat 10 mg

91

69 (12)

77 (84.6)

28 (5)

29.3 (8.3)

4511 (5197)

60.0 (19.6)

49 (53.8)

32 (35.2)

78 (85.7)

35 (38.5)

46 (50.5)

Placebo

92

67 (13)

73 (79.3)

27 (5)

28.6 (8.5)

4239 (3577)

57.8 (17.4)

41 (44.6)

30 (32.6)

70 (76.1)

38 (41.3)

51 (55.4)

Pieske et al. 2017 (SOCRATES-PRESERVED) [12]

Vericiguat 1.25 mg

96

74 (10)

45 (46.9)

29.6 (6.5)

56.3 (5.3)

1376.7 (1631)

52.8 (23.0)

48 (50.0)

41 (42.7)

86 (89.6)

48 (50.0)

N/A

N/A

Vericiguat 2.5 mg

96

72 (11)

53 (55.2)

30.7 (6.3)

57 (7.5)

1268 (1413.5)

57.4 (20.8)

46 (47.9)

40 (41.7)

85 (88.5)

34 (35.4)

N/A

N/A

Vericiguat 5 mg

96

74 (8)

53 (55.2)

30.1 (5.6)

57.7 (6.8)

1700 (2289)

54.2 (17.3)

47 (49.0)

38 (39.6)

86 (89.6)

33 (34.4)

N/A

N/A

Vericiguat 10 mg

96

73 (10)

52 (54.2)

30.4 (5.0)

56.3 (5.3)

1527 (1643)

57.4 (19.3)

44 (45.8)

36 (37.5)

90 (93.8)

38 (39.6)

N/A

N/A

Placebo

93

74 (9)

47 (50.5)

30.1 (6.5)

57.3 (6.8)

1360 (1540)

52.3 (20.6)

47 (50.5)

35 (37.6)

85 (91.4)

43 (46.2)

N/A

N/A

Udelson et al. 2020 (CAPACITY HFpEF) [11]

Praliciguat 40 mg

91

70.7 (9.2)

56 (61.5)

34.1 (6.1)

61.9 (7.5)

1516 (3221)

65.4 (20.0)

46 (50.5)

14 (15.4)

90 (98.9)

24 (26.4)

N/A

36 (39.6)

Placebo

90

70.1 (9.0)

50 (55.6)

34.7 (7.3)

59.8 (9.3)

1792 (3864)

68.6 (21.7)

50 (55.6)

17 (18.9)

87 (96.7)

14 (15.6)

35 (38.9)

Study ID

Arm

Number of patients

Age (years), mean (SD)

Gender (male), N. (%)

BMI, mean (SD)

LVEF (%), mean (SD)

NT-proBNP, mean (SD)

eGFR, mean (SD)

Concomitant medication, N. (%)

Diuretics

ACEIs

ARBs

BBs

CBBs

Anti-coagulants

Anti-platelets

MRAs

Armstrong et al. 2020 (VITALITY-HFpEF) [8]

Vericiguat 10 mg

263

72.2 (9.7)

139 (52.9)

30.4 (6.0)

55.8 (8.3)

1700 (1732)

62.4 (20.6)

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

Vericiguat 15 mg

264

73.1 (9.1)

124 (47.0)

30.9 (6.2)

56.8 (7.9)

2826.5(1639)

59.1 (21.2)

N/A

N/A

N/A

N/A

N/A

N/A

N/A

c

Placebo

262

72.8 (9.4)

141 (53.8)

30.7 (6.0)

56.3 (7.9)

1867 (1763.2)

56.9 (20.0)

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

Armstrong et al. 2020 (VICTORIA) [2]

Vericiguat 10 mg

2526

67.5 (12.2)

1921 (76)

27.7 (5.8)

29 (8.3)

3139.75 (1116.3)

61.3 (27)

N/A

1847 (73.3)

2349 (93.2)

N/A

N/A

 

N/A

 

Placebo

2524

67.2 (12.2)

1921 (76.1)

27.9 (6.1)

28.8 (8.3)

3099 (1068.1)

61.7 (27.3)

N/A

1853 (73.6)

2342 (93)

N/A

N/A

 

N/A

 

Bonderman et al. 2013 (LEPHT) [10]

Riociguat 0.5 mg

26

57.2 (36–78)

26 (81)

29.2 (5.7)

27 (5)

1923 (1411.8)

72 (18.1)

29 (91)

21 (66)

10 (31)

32 (100)

N/A

15 (47)

N/A

23 (72)

Riociguat 1 mg

30

55.1 (28–74)

30 (91)

28.2 (4.6)

28.8 (4.6)

2417 (2730.4)

72.6 (23)

31 (94)

25 (76)

8 (24)

32 (94)

N/A

16 (49)

N/A

26 (79)

Riociguat 2 mg

55

59.3 (26–76)

55 (82)

28.9 (4.9)

28.4 (5.7)

2175 (2335.2)

65.1 (18.8)

62 (93)

50 (75)

20 (30)

61 (91)

N/A

38 (57)

N/A

51 (76)

Placebo

61

58.9 (25–79)

61 (88)

28.7 (5.8)

27.1 (5)

3000 (3472.2)

68.7 (19.9)

66 (96)

46 (67)

19 (28)

62 (90)

N/A

33 (48)

N/A

53 (77)

Bonderman et al. 2014 (DILATE-1) [7]

Riociguat 0.5 mg

8

68.3 (48.0–80.0)

1 (13)

33.5 (22.9–44.9)

N/A

1765 (1323)

N/A

6 (76)

2 (25)

5 (63)

5 (63)

3 (38)

6 (75)

N/A

2 (25)

Riociguat 1 mg

7

65.3 (52.0–79.0)

3 (43)

31.0 (21.6–40.8)

N/A

852 (444)

N/A

5 (72)

6 (86)

1 (14)

6 (86)

2 (29)

5 (71)

N/A

6 (86)

Riociguat 2 mg

10

72.8 (59.0–83.0)

5 (50)

29.3 (23.5–33.4)

N/A

2537 (2394)

N/A

5 (50)

6 (60)

2 (20)

8 (80)

5 (50)

5 (50)

N/A

8 (80)

Placebo

11

75.1 (65.0–86.0)

6 (45)

30.2 (21.8–36.0)

N/A

2195 (1316)

N/A

9 (82)

3 (27)

5 (45)

10 (91)

6 (55)

7 (64)

N/A

7 (64)

Dachs et al. 2022 (haemoDYNAMIC) [9]

Riociguat up-titrated 1.5 mg

58

70.6 (8.0)

12 (20.7)

32.1 (6.4)

61.0 (6.7)

819.6

63.4 (21.9)

47 (81)

42 (72.4)

43 (74.1)

N/A

34 (58.6)

40 (79)

8(13.8)

 

Placebo

56

72.1 (8.5)

19 (33.9)

30.3 (6.4)

60.1 (6.0)

1051.3

61.7 (20.1)

49 (87.5)

40 (71.4)

42 (75.0)

N/A

31 (55.4)

42 (75)

13 (23.2)

 

Gheorghiade et al. 2015 (SOCRATES-Reduced) [6]

Vericiguat 1.25 mg

91

68 (13)

70 (76.9)

28 (6)

29.5 (8.6)

3529 (3562)

57.2 (21.0)

82 (90.1)

59 (64.8)

17 (18.7)

77 (84.6)

N/A

N/A

N/A

51 (56)

Vericiguat 2.5 mg

91

68 (12)

72 (79.1)

28 (5)

29.2 (8.2)

2921 (2452)

56.9 (19.1)

87 (95.6)

60 (65.9)

18 (19.8)

79 (86.8)

  

N/A

61 (67)

Vericiguat 5 mg

91

67 (12)

74 (81.3)

29 (5)

31.5 (8.5)

4229 (5248)

60.1 (20.2)

84 (92.3)

53 (58.2)

29 (31.9)

86 (94.5)

  

N/A

58 (63.7)

Vericiguat 10 mg

91

69 (12)

77 (84.6)

28 (5)

29.3 (8.3)

4511 (5197)

60.0 (19.6)

91 (100.0)

56 (61.5)

19 (20.9)

86 (94.5)

  

N/A

64 (70.3)

Placebo

92

67 (13)

73 (79.3)

27 (5)

28.6 (8.5)

4239 (3577)

57.8 (17.4)

86 (93.5)

52 (56.5)

21 (22.8)

83 (90.2)

  

N/A

50 (54.3)

Pieske et al. 2017 (SOCRATES-PRESERVED) [12]

Vericiguat 1.25 mg

96

74 (10)

45 (46.9)

29.6 (6.5)

56.3 (5.3)

1376.7 (1631)

52.8 (23.0)

91 (94.8)

42 (43.8)

32 (33.3)

73 (76.0)

38 (39.6)

N/A

N/A

37 (38.5)

Vericiguat 2.5 mg

96

72 (11)

53 (55.2)

30.7 (6.3)

57 (7.5)

1268 (1413.5)

57.4 (20.8)

85 (88.5)

41 (42.7)

33 (34.4)

76 (79.2)

40 (41.7)

 

N/A

34 (35.4)

Vericiguat 5 mg

96

74 (8)

53 (55.2)

30.1 (5.6)

57.7 (6.8)

1700 (2289)

54.2 (17.3)

88 (92.6)

33 (34.7)

31 (32.6)

73 (76.8)

30 (31.6)

 

N/A

35 (36.8)

Vericiguat 10 mg

96

73 (10)

52 (54.2)

30.4 (5.0)

56.3 (5.3)

1527 (1643)

57.4 (19.3)

90 (93.8)

35 (36.5)

34 (35.4)

82 (85.4)

33 (34.4)

 

N/A

33 (34.4)

Placebo

93

74 (9)

47 (50.5)

30.1 (6.5)

57.3 (6.8)

1360 (1540)

52.3 (20.6)

85 (91.4)

40 (43.0)

32 (34.4)

76 (81.7)

30 (32.3)

 

N/A

39 (41.9)

Udelson et al. 2020 (CAPACITY HFpEF) [11]

Praliciguat 40 mg

91

70.7 (9.2)

56 (61.5)

34.1 (6.1)

61.9 (7.5)

1516 (3221)

65.4 (20.0)

17 (18.7)

27 (29.7)

2 (2.2)

39 (42.9)

28 (30.8)

21 (23.1)

63 (69.2)

N/A

Placebo

90

70.1 (9.0)

50 (55.6)

34.7 (7.3)

59.8 (9.3)

1792 (3864)

68.6 (21.7)

17 (18.9)

36 (40.0)

3 (3.3)

24 (26.7)

26 (28.9)

17 (18.9)

60 (66.7)

N/A

  1. N/A not available, SD standard deviation, N number, BMI basal metabolic index, LVEF left ventricular ejection fraction, NT-proBNP N-terminal pro-brain natriuretic peptide, eGFR estimated glomerular filtration rate, DM diabetes mellitus, AF atrial fibrillation, HTN hypertension, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, CAD coronary artery disease, ACEIs angiotensin converting enzyme inhibitors, ARBs angiotensinogen receptor blockers, BBs beta blockers, CCBs calcium channel blockers, MRAs mineralocorticoid antagonists
Back to article page